Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified a novel cytoplasmic protein,
leupaxin
, that is preferentially expressed in hematopoietic cells and is most homologous to the focal adhesion protein, paxillin.
Leupaxin
possesses two types of protein interaction domains. There are four carboxyl-terminal LIM domains in
leupaxin
that share 70% amino acid identity and 80% similarity with those in paxillin. Paxillin LIM domains mediate localization to focal contacts. In the amino-terminal region of
leupaxin
there are three short stretches of approximately 13 amino acids that share 70-90% similarity with paxillin LD motifs. Paxillin LD motifs have been implicated in
focal adhesion kinase
(
FAK
) and vinculin binding resulting in the localization of
FAK
to focal adhesions.
Leupaxin
is expressed in cell types, such as macrophage, that lack
FAK
. We demonstrate here that
leupaxin
associates with a second
FAK
family member,
PYK2
. As
leupaxin
and
PYK2
are both preferentially expressed in leukocytes they may therefore form a cell type-specific signaling complex. We also demonstrate that
leupaxin
is a substrate for a tyrosine kinase in lymphoid cells and thus may function in and be regulated by tyrosine kinase activity.
Leupaxin
is thus a phosphotyrosine protein with LD and LIM binding motifs most homologous to paxillin that may assemble and regulate
PYK2
signaling complexes in leukocytes.
...
PMID:Leupaxin is a novel LIM domain protein that forms a complex with PYK2. 956 92
Paxillin is a focal adhesion scaffolding protein, which has been proposed to play a role in focal adhesion dynamics. We have isolated a cDNA clone of the Drosophila homologue of paxillin. Comparison of the Drosophila paxillin sequence with those of vertebrate paxillins shows strong conservation of the LIM domains and LD repeats. Using the Drosophila genomic sequence we have identified two partial curated transcripts and deduced the structure of the paxillin gene. No homologues of other members of the paxillin family such as HIC-5 or
leupaxin
are to be found in the Drosophila genome. Surprisingly paxillin mRNA is expressed in a restricted pattern during embryogenesis. In particular it is strongly expressed in cells and tissues undergoing cell shape changes or cell migration. Many of the sites of expression are also known to be sites of integrin function or
FAK
expression. The data support a role for paxillin as an adapter and/or signaling protein during developmental processes involving integrin-mediated adhesion.
...
PMID:The cloning, genomic organization and expression of the focal contact protein paxillin in Drosophila. 1117 95
Leupaxin
is a cytoskeleton adaptor protein that was first identified in human macrophages and was found to share homology with the focal adhesion protein, paxillin.
Leupaxin
possesses several protein-binding domains that have been implicated in targeting proteins such as
focal adhesion kinase
(pp125FAK) to focal adhesions.
Leupaxin
can be detected in monocytes and osteoclasts, both cells of hematopoietic origin. We have identified
leupaxin
to be a component of the osteoclast podosomal signaling complex. We have found that
leupaxin
in murine osteoclasts is associated with both
PYK2
and pp125FAK in the osteoclast. Treatment of osteoclasts with TNF-alpha and soluble osteopontin were found to stimulate tyrosine phosphorylation of both
leupaxin
and
leupaxin
-associated
PYK2
.
Leupaxin
was found to co-immunoprecipitate with the protein tyrosine phosphatase PTP-PEST. The cellular distribution of
leupaxin
,
PYK2
, and protein tyrosine phosphorylation-PEST co-localized at or near the osteoclast podosomal complex.
Leupaxin
was also found to associate with the ARF-GTPase-activating protein, paxillin kinase linker p95PKL, thereby providing a link to regulators of cytoskeletal dynamics in the osteoclast. Overexpression of
leupaxin
by transduction into osteoclasts evoked numerous cytoplasmic projections at the leading edge of the cell, resembling a motile phenotype. Finally, in vitro inhibition of
leupaxin
expression in the osteoclast led to a decrease in resorptive capacity. Our data suggest that
leupaxin
may be a critical nucleating component of the osteoclast podosomal signaling complex.
...
PMID:Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. 1267 28
Leupaxin
is a LIM domain-containing adapter protein belonging to the paxillin family that has been previously reported to be preferentially expressed in hematopoietic cells. Herein, we identified
leupaxin
in a screen for
focal adhesion kinase
binding partners in aortic smooth muscle, and we show that
leupaxin
is enriched in human and mouse vascular smooth muscle and that
leupaxin
expression is dynamically regulated during development. In addition, our studies reveal that
leupaxin
can undergo cytoplasmic/nuclear shuttling and functions as an serum response factor cofactor in the nucleus. We found that
leupaxin
forms a complex with serum response factor and associates with CArG-containing regions of smooth muscle promoters and that ectopic expression of
leupaxin
induces smooth muscle marker gene expression in both 10T1/2 cells and rat aortic smooth muscle cells. Subsequent studies indicated that enhanced
focal adhesion kinase
activity (induced by fibronectin or expression of constitutively active
focal adhesion kinase
) attenuates the nuclear accumulation of
leupaxin
and limits the ability of
leupaxin
to enhance serum response factor-dependent gene transcription. Thus, these studies indicate that modulation of the subcellular localization of serum response factor cofactors is 1 mechanism by which extracellular matrix-dependent signals may regulate phenotypic switching of smooth muscle cells.
...
PMID:The LIM protein leupaxin is enriched in smooth muscle and functions as an serum response factor cofactor to induce smooth muscle cell gene transcription. 1849 31
Focal adhesion (FA) consists of multiple cellular proteins including paxillin and serves as a center for adhesion-mediated signaling. The assembly and disassembly of FAs is regulated by locally produced intracellular signals, and tyrosine phosphorylation of paxillin has been implicated in this process. A Lin-11 Isl-1 Mec-3 (LIM) domain-containing adaptor protein,
leupaxin
, a member of the paxillin family, is expressed in leukocytes as well as in certain cancer cells, and shares overall structural characteristics with paxillin. However, it remains unknown whether
leupaxin
and paxillin cooperate with or antagonize each other in integrin signaling. Here we show that
leupaxin
potently represses the tyrosine phosphorylation of paxillin. When expressed in mouse thymoma BW5147 cells bound to ICAM-1,
leupaxin
accumulated in FA-like patches in the cell periphery. When expressed in NIH3T3 and HEK293T cells,
leupaxin
localized to FAs upon cell adhesion to fibronectin and strongly suppressed the integrin-induced tyrosine phosphorylation of paxillin. In integrin-stimulated HEK293T cells,
leupaxin
's LIM3 domain appeared essential for selective FA localization and the suppression of paxillin tyrosine phosphorylation.
Leupaxin
's LD3 motif, which is critical for stable association with
FAK
, was dispensable for
leupaxin
's suppressive ability. In addition,
leupaxin
reduced the spreading of NIH3T3 cells on fibronectin, which required both the LD3 motif and LIM3 domain. When expressed in human leukocytic K562 cells,
leupaxin
significantly suppressed integrin alpha5beta1-mediated cell adhesion to fibronectin and the tyrosine phosphorylation of paxillin. These findings indicate that
leupaxin
functions as a paxillin counterpart that potently suppresses the tyrosine phosphorylation of paxillin during integrin signaling.
...
PMID:LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and suppresses the integrin-induced tyrosine phosphorylation of paxillin. 1991 54
Proline-rich tyrosine kinase 2 (Pyk2) is a nonreceptor tyrosine kinase and belongs to the
focal adhesion kinase
(
FAK
) family. Like
FAK
, the C-terminal focal adhesion-targeting (FAT) domain of Pyk2 binds to paxillin, a scaffold protein in focal adhesions; however, the interaction between the FAT domain of Pyk2 and paxillin is dynamic and unstable.
Leupaxin
is another member in the paxillin family and was suggested to be the native binding partner of Pyk2; Pyk2 gene expression is strongly correlated with that of
leupaxin
in many tissues including primary breast cancer. Here, we report that
leupaxin
interacts with Pyk2-FAT.
Leupaxin
has four leucine-aspartate (LD) motifs. The first and third LD motifs of
leupaxin
preferably target the two LD-binding sites on the Pyk2-FAT domain, respectively. Moreover, the full-length
leupaxin
binds to Pyk2-FAT as a stable one-to-one complex. Together, we propose that there is an underlying selectivity between
leupaxin
and paxillin for Pyk2, which may influence the differing behavior of the two proteins at focal adhesion sites.
...
PMID:Structural Basis for the Interaction between Pyk2-FAT Domain and Leupaxin LD Repeats. 2686 73
The
focal adhesion kinase
(
FAK
) and the proline-rich tyrosine kinase 2-beta (PYK2) are implicated in cancer progression and metastasis and represent promising biomarkers and targets for cancer therapy.
FAK
and PYK2 are recruited to focal adhesions (FAs) via interactions between their FA targeting (FAT) domains and conserved segments (LD motifs) on the proteins Paxillin,
Leupaxin
, and Hic-5. A promising new approach for the inhibition of
FAK
and PYK2 targets interactions of the
FAK
domains with proteins that promote localization at FAs. Advances toward this goal include the development of surface plasmon resonance, heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) and fluorescence polarization assays for the identification of fragments or compounds interfering with the
FAK
-Paxillin interaction. We have recently validated this strategy, showing that Paxillin mimicking polypeptides with 2 to 3 LD motifs displace
FAK
from FAs and block kinase-dependent and independent functions of
FAK
, including downstream integrin signaling and FA localization of the protein p130Cas. In the present work we study by all-atom molecular dynamics simulations the recognition of peptides with the Paxillin and
Leupaxin
LD motifs by the
FAK
-FAT and PYK2-FAT domains. Our simulations and free-energy analysis interpret experimental data on binding of Paxillin and
Leupaxin
LD motifs at
FAK
-FAT and PYK2-FAT binding sites, and assess the roles of consensus LD regions and flanking residues. Our results can assist in the design of effective inhibitory peptides of the
FAK
-FAT: Paxillin and PYK2-FAT:
Leupaxin
complexes and the construction of pharmacophore models for the discovery of potential small-molecule inhibitors of the
FAK
-FAT and PYK2-FAT focal adhesion based functions.
...
PMID:Recognition of LD motifs by the focal adhesion targeting domains of focal adhesion kinase and proline-rich tyrosine kinase 2-beta: Insights from molecular dynamics simulations. 3277 36